Epithelioid sarcoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
===Chemotherapy=== | ===Chemotherapy=== | ||
* Doxorubicin is the drug of choice. | * Doxorubicin is the drug of choice. | ||
* The gold standard for chemotherapy is a combination of [[doxorubicin]] and [[ifosfamide]]. However, recent studies have suggested that the addition of ifosfamide to doxorubicin does not necessarily lead to an increase in overall survival.<ref>{{cite journal |last1=Judson |first1=Ian |last2=Verweij |first2=Jaap |last3=Gelderblom |first3=Hans |last4=Hartmann |first4=Jörg T |last5=Schöffski |first5=Patrick |last6=Blay |first6=Jean-Yves |last7=Kerst |first7=J Martijn |last8=Sufliarsky |first8=Josef |last9=Whelan |first9=Jeremy |last10=Hohenberger |first10=Peter |last11=Krarup-Hansen |first11=Anders |last12=Alcindor |first12=Thierry |last13=Marreaud |first13=Sandrine |last14=Litière |first14=Saskia |last15=Hermans |first15=Catherine |last16=Fisher |first16=Cyril |last17=Hogendoorn |first17=Pancras C W |last18=dei Tos |first18=A Paolo |last19=van der Graaf |first19=Winette T A |title=Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial |journal=The Lancet Oncology |volume=15 |issue=4 |pages=415–23 |year=2014 |pmid=24618336 |doi=10.1016/S1470-2045(14)70063-4 }}</ref> [[Etoposide]], [[vincristine]], [[dactinomycin]], and [[cyclophosphamide]] have also traditionally been given.<ref name="NCCN Soft Tissue Sarcoma"/> Newer chemotherapies, such as [[gemcitabine]] and [[pazopanib]], are currently being tested in clinical trials. | |||
===Radiation Therapy=== | ===Radiation Therapy=== | ||
* Radiation Therapy was used for limb salvage therapy. | * Radiation Therapy was used for limb salvage therapy. | ||
Revision as of 16:01, 11 February 2016
|
Epithelioid sarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Epithelioid sarcoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Epithelioid sarcoma medical therapy |
|
Risk calculators and risk factors for Epithelioid sarcoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Medical Therapy
Chemotherapy
- Doxorubicin is the drug of choice.
- The gold standard for chemotherapy is a combination of doxorubicin and ifosfamide. However, recent studies have suggested that the addition of ifosfamide to doxorubicin does not necessarily lead to an increase in overall survival.[1] Etoposide, vincristine, dactinomycin, and cyclophosphamide have also traditionally been given.[2] Newer chemotherapies, such as gemcitabine and pazopanib, are currently being tested in clinical trials.
Radiation Therapy
- Radiation Therapy was used for limb salvage therapy.
Complications of Radiation Therapy
- Scarring
- Stiffness
- Neuropathy
References
- ↑ Judson, Ian; Verweij, Jaap; Gelderblom, Hans; Hartmann, Jörg T; Schöffski, Patrick; Blay, Jean-Yves; Kerst, J Martijn; Sufliarsky, Josef; Whelan, Jeremy; Hohenberger, Peter; Krarup-Hansen, Anders; Alcindor, Thierry; Marreaud, Sandrine; Litière, Saskia; Hermans, Catherine; Fisher, Cyril; Hogendoorn, Pancras C W; dei Tos, A Paolo; van der Graaf, Winette T A (2014). "Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial". The Lancet Oncology. 15 (4): 415–23. doi:10.1016/S1470-2045(14)70063-4. PMID 24618336.
- ↑ Invalid
<ref>tag; no text was provided for refs namedNCCN Soft Tissue Sarcoma